Walleye Capital’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Walleye Capital’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,282,334	Closed	-$24.5K	–	5178
2023 Q1	$24.5K	Sell	1,282,334 -41,374	-3%	-$3.98K	﹤0.01%	3364
2022 Q4	$197K	Buy	1,323,708 +556,316	+72%	+$89K	﹤0.01%	2061
2022 Q3	$130K	Buy	767,392 +749,551	+4,201%	+$110K	﹤0.01%	2319
2022 Q2	$2K	Hold	17,841	–	–	﹤0.01%	2271
2022 Q1	$14K	Sell	17,841 -1,918	-10%	-$1.34K	﹤0.01%	2037
2021 Q4	$12K	Sell	19,759 -2,951	-13%	-$3K	﹤0.01%	2013
2021 Q3	$22	Hold	22,710	–	–	﹤0.01%	1483
2021 Q2	$34	Buy	+22,710	New	+$19.8K	﹤0.01%	1262

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Walleye Capital's PEARW Position: Q2 2023 in Review

Walleye Capital sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 1,282,334 shares — an estimated $24.5K sold.

Walleye Capital first reported a position in PEARW in Q2 2021 and held it in 8 quarters. The position peaked at $197K in Q4 2022. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Walleye Capital reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 1,282,334 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $24.5K.
Walleye Capital first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 8 quarters.
Walleye Capital's Pear Therapeutics, Inc. Warrant position peaked at $197K in Q4 2022.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.